Lumefantrine

Ethambutol is a bacteriostatic antimycobacterial drug prescribed to treat tuberculosis (Mycobacterium tuberculosis). It is usually given in combination with other tuberculosis drugs, such as isoniazid, pyrazinamide and rifampicin.

It is sold under the name "Myambutol".

Bacteriostatic against actively growing TB bacilli, it works by obstructing the formation of cell wall. Mycolic acids attach to the 5'-hydroxyl groups of D-arabinose residues of arabinogalactan and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall.

Ethambutol is a bacteriostatic antimycobacterial drug prescribed to treat tuberculosis (Mycobacterium tuberculosis). It is usually given in combination with other tuberculosis drugs, such as isoniazid, pyrazinamide and rifampicin.

It is sold under the name "Myambutol".

Bacteriostatic against actively growing TB bacilli, it works by obstructing the formation of cell wall. Mycolic acids attach to the 5'-hydroxyl groups of D-arabinose residues of arabinogalactan and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall.

Rifampicin (inn) (pronounced /r? 'fæmp? S? N/) or rifampin (usan) is a bactericidal[1] antibiotic drug of the rifamycin group. It is a semisynthetic compound derived from amycolatopsis rifamycinica (formerly known as amycolatopsis mediterranei and streptomyces mediterranei). Rifampicin may be abbreviated rif, rmp, rd, ra or r. It is also known as rifaldazine, r/amp, and rofact (in canada. ) there are various types of rifamycins from which this is derived, but this particular form, with a 4-methyl-1-piperazinaminyl group, is by far the most clinically effective.

Lovastatin is a member of the drug class of statins, used for lowering cholesterol (hypolipidemic agent) in those with hypercholesterolemia and so preventing cardiovascular disease.

Simvastatin (INN) (pronounced /'smvstætn/), initially marketed under the trade name Zocor, is a hypolipidemic drug belonging to the class of pharmaceuticals called "statins". It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus.

Compactin, an inhibitor of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase, decreased cholesterol synthesis in intact Hep G2 cells. However, after the inhibitor was washed away, the HMG-CoA-reductase activity determined in the cell homogenate was found to be increased. Also the high-affinity association of LDL (low-density lipoprotein) to Hep G2 cells was elevated after incubation with compactin. Lipoprotein-depleted serum, present in the incubation medium, potentiated the compactin effect compared with incubation in the presence of human serum albumin. Addition of either mevalonate or LDL prevented the compactin-induced rise in activities of both HMG-CoA reductase and LDL receptor in a comparable manner.

There are several classes of hypolipidemic drugs. They may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower the "bad cholesterol" low density lipoprotein (LDL) more so than others, while others may preferentially increase high density lipoprotein (HDL), "the good cholesterol". Clinically, the choice of an agent will depend on the patient's cholesterol profile, cardiovascular risk, and the liver and kidney functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the evidence-based guideline from the National Cholesterol Education Program (NCEP) Adult Treatment Panel III.

Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease. Initially known as CS-514, it was originally identified in a bacterium called Nocardia autotrophica by researchers of the Sankyo Pharma Inc..[1] It is presently being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb.